Liquidia Corp Announces FDA Fast Track for YUTREPIA in Raynaud's

What Happened

• On September 3, 2026, Liquidia Corporation (Nasdaq: LQDA) announced via press release (filed as Exhibit 99.1 to an 8‑K) that the U.S. Food and Drug Administration granted Fast Track Designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud’s phenomenon associated with systemic sclerosis.

Key Details

• Date of announcement: September 3, 2026.
• Product: YUTREPIA® (treprostinil) inhalation powder.
• Indication: Raynaud’s phenomenon associated with systemic sclerosis.
• Filing: Press release attached as Exhibit 99.1 to the Form 8‑K.

Why It Matters

• Fast Track is an FDA program intended to facilitate development and expedite review for drugs addressing serious conditions with unmet medical needs. For investors, this designation can mean more frequent FDA interaction, potential eligibility for rolling review, and possibly faster regulatory timelines — factors that could affect the program’s development pace and value. The 8‑K does not include financial results or other operational details.